BridgeMD
New treatment option for Type 1 Diabetes
Official title A Trial of Three- and Seven-days Insulin Infusions Set
ClinicalTrials.gov ID: NCT06532461
What this study is testing
What is Novorapid?
Novorapid is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for type 1 diabetes.
Also referred to as Humalog.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- More and more children and adolescents are using diabetes devices attached to the skin. The attachment of infusions sets to the skin provoke allergenic or toxic eczema, the continous infusion of insulin provoke subcutaneous changes and prolonged wear time seems to increase the risk of these complication.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 7 to 18
You may be able to join if
- Diagnosed with T1D
- Diabetes duration of more than 6 months prior to inclusion.
- Currently using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery.
- Planning to using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery.
- Being between 7 and 18 years of age prior to inclusion
You likely can't join if
- Those who are unable to read and understand Danish
- Those with impaired cognitive development that may interfere with the ability to answer questionnaires in Danish and/or be reached by phone or...
See the full eligibility criteria
- Diagnosed with T1D
- Diabetes duration of more than 6 months prior to inclusion.
- Currently using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery.
- Planning to using the CE-marked hybrid closed-loop system - Medtronic 780G pump and the corresponding sensor with automated insulin delivery.
- Being between 7 and 18 years of age prior to inclusion
- Insulin needs per day above 8 units
- Those who are unable to read and understand Danish
- Those with impaired cognitive development that may interfere with the ability to answer questionnaires in Danish and/or be reached by phone or videocall
The study team makes the final eligibility decision.
Where it's taking place
- Herlev, Capital, Denmark
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 7 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Herlev, Capital, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.